

10649255

=> s 13

L4 6 L3

=> d his

(FILE 'HOME' ENTERED AT 11:54:54 ON 04 JUN 2004)

FILE 'REGISTRY' ENTERED AT 11:55:06 ON 04 JUN 2004

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 54 S L1 SSS FULL


FILE 'CAPLUS' ENTERED AT 11:56:04 ON 04 JUN 2004

L4 6 S L3

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 1-6 bib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:392324 CAPLUS

TI Preparation of alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolopyridines as MAP kinases, in particular p38 kinase inhibitors

IN Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 31 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
-------	-------	-------	-------	-------

PI US 2004092547	A1	20040513	US 2003-649227	20030827
------------------	----	----------	----------------	----------

PRAI US 2002-407088P	P	20020830		
----------------------	---	----------	--	--

GI




AB Title compds. I [wherein R₁ = F; n = 2; R₂ = alkyl, optionally substituted by halo, OH, alkoxy, and alkoxy carbonyl; with certain compds. absent; their pharmaceutically acceptable salts] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, II was prepared by Pd-cross coupling of 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine (preparation given) with 2,5-difluoroboronic acid in the presence of TEA/EtOH/H₂O. Selected I had an IC₅₀ <10 μM in the TNF-α and MAPKAP in vitro assays, and an EC₅₀ <50 mg/kg in the in vivo TNFα assay. I are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

IT 668981-02-0P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
 RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (p38 kinase inhibitor; preparation of alkyldifluorophenoxyazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)

RN 668981-02-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 459448-00-1P 668981-03-1P, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
 668981-04-2P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride 668981-05-3P,
 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate 668981-06-4P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate 668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate 668990-77-0P, 3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-78-1P,
 3-tert-Butyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-97-4P, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; preparation of alkyldifluorophenoxyazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)


RN 459448-00-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)


10649255



RN 668981-03-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 668981-05-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 668981-02-0
CMF C18 H14 F2 N4 O



10649255

CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 668981-06-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2


CRN 104-15-4
CMF C7 H8 O3 S



RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 668981-02-0
CMF C18 H14 F2 N4 O




CM 2

10649255


CRN 7664-93-9
CMF H₂ O₄ S




RN 668990-77-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 668990-78-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 668990-97-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:372880 CAPLUS
DN 140:391284
TI Preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase
IN Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 24 pp.

10649255


CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004087615	A1	20040506	US 2003-649255	20030827
PRAI	US 2002-407489P	P	20020830		
GI					




AB The title compds. [I; R1 = F; s = 2; R2 = (un)substituted cycloalkyl] which are potent inhibitors of MAP kinases, preferably p38 kinase, and therefore useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders, were prepared. E.g., a multi-step synthesis of II, starting from 2,5-dibromopyridine, was given. The pharmaceutical composition comprising the compound I is claimed.

IT 668990-79-2P, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)

RN 668990-79-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




IT 668990-83-8P, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine 668990-84-9P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)[1,2,4]triazolo[4,3-a]pyridine 668990-85-0P, 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)[1,2,4]triazolo[4,3-a]pyridine 668990-86-1P, 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines as potent inhibitors of MAP kinases, preferably p38 kinase)


RN 668990-83-8 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)


10649255




RN 668990-84-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 668990-85-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 668990-86-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:331789 CAPLUS
DN 140:357352
TI Preparation of 3-alkyl-6-[4-(trifluorophenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridines as potent inhibitors of MAP kinases


10649255

IN Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004077682	A1	20040422	US 2003-649265	20030827
PRAI	US 2002-407089P	P	20020830		
OS	MARPAT 140:357352				
GI					



AB The title compds. [I; R₁ = F; s = 3; R₂ = alkyl optionally substituted by halo, OH, alkoxy, etc.] which are potent inhibitors of MAP kinases, preferably p38 kinase, were prepared. Thus, reacting [α -(p-toluenesulfonyl)-2,4,5-trifluorobenzyl]isonitrile with 3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxaldehyde (preps. given) in the presence of K₂CO₃ in MeCN at 70°C for 22 h afforded 48% II. All compds. I that were tested had an IC₅₀ of <10 μ M in the TNF α and MAPKAP in vitro assays and ED₅₀ of <50 mg/kg in the in vivo TNF α assay. The compds. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. The pharmaceutical composition comprising the compound I is claimed.


IT 668990-87-2P 668990-90-7P 668990-91-8P
668990-92-9P 668990-93-0P 668990-94-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-alkyl-6-[4-(trifluorophenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridines as potent inhibitors of MAP kinases)

RN 668990-87-2 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-90-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)


10649255




RN 668990-91-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-92-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,6-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-93-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-94-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1,1-dimethylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:203834 CAPLUS
 DN 140:235722
 TI Preparation of 6-[4-(di- or trifluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine as inhibitors of mitogen-activated protein (MAP) kinases
 IN Dombroski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 87 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004020440	A1	20040311	WO 2003-IB3847	20030819
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004053958	A1	20040318	US 2003-649236	20030827
PRAI	US 2002-407177P	P	20020830		
OS	MARPAT	140:235722			
GI					



AB The present invention relates to novel triazolo-pyridines of the formula (I) [wherein R1 is fluoro; m = 2,3; R2 is C3-6 cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-4 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; or R2 is C1-6 alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-6 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; with the proviso that said compound of this formula cannot be 6-[4-(2,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine or 6-[4-(3,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine] or


pharmaceutically acceptable salt thereof; to intermediates for their preparation, and to pharmaceutical compns. containing them and to their medicinal use. The compds. I are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, a mixture of $[\alpha$ -(p-toluenesulfonyl)-2,6-difluorobenzyl]isonitrile (1.79 g, 5.84 mmol), 3-isopropyl-[1,2,4]triazolo[4,3-a]-6-pyridinecarboxaldehyde > (1.10 g, 5.84 mmol), potassium carbonate (1.05 g, 7.59 mmol) and acetonitrile (17.5 mL) was refluxed for 22 h to give, after workup and silica gel chromatog., 6-[4-(2,6-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine as a yellow solid. A tablet formulation containing 6-[4-(2,5-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine was prepared, which can be administered to a human from one to four times a day for inhibiting cartilage damage or treating osteoarthritis.

IT 668981-02-0P

RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(X-ray crystallog. data and polymorphism; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668981-02-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 668990-79-2P, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668990-79-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



IT 668981-03-1P, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine 668981-04-2P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride 668981-05-3P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate 668981-06-4P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate 668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate 668990-77-0P,

10649255


3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-78-1P, 3-tert-Butyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-83-8P, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-84-9P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine 668990-85-0P, 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine 668990-86-1P, 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-87-2P, 3-Isopropyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-90-7P, 3-Isopropyl-6-[4-(2,3,4-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-91-8P, 3-Isopropyl-6-[4-(2,3,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-92-9P, 3-Isopropyl-6-[4-(2,4,6-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-93-0P, 3-Isopropyl-6-[4-(3,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-94-1P, 3-tert-Butyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-95-2P, 3-Cyclopropyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-96-3P, 3-(1-Methylcyclopropyl)-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-97-4P, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)


RN 668981-03-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 668981-05-3 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O

10649255



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 668981-06-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 668981-02-0
CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 668981-07-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 668981-02-0
CMF C18 H14 F2 N4 O

10649255




CM 2


CRN 7664-93-9
CMF H₂ O₄ S



RN 668990-77-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 668990-78-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 668990-83-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

10649255




RN 668990-84-9 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)




RN 668990-85-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 668990-86-1 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(2,5-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-87-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)


10649255




RN 668990-90-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,4-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-91-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,3,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-92-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(2,4,6-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-93-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)


10649255




RN 668990-94-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1,1-dimethylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-95-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 668990-96-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylcyclopropyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 668990-97-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:203832 CAPLUS
DN 140:235721
TI Novel processes and intermediates for preparing [1,2,4]triazolo[4,3-a]pyridines
IN Buzon, Richard Allen Sr.; Castaldi, Michael James; Li, Zhengong Bryan;
Ripin, David Harold Brown; Tao, Yong
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004020438	A2	20040311	WO 2003-IB3669	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KB, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004053959	A1	20040318	US 2003-649247	20030827
PRAI US 2002-407085P	P	20020830		
OS CASREACT 140:235721; MARPAT 140:235721				
GI				



AB The present invention relates and intermediates to a novel process for preparing triazolo-pyridines of the formula (I) [R1 = H, cyano, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl or NH2; R3 = halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, perhalo-C1-6 alkyl, Ph, C1-10 heteroaryl,


C1-10 heterocyclyl, C3-10 cycloalkyl, HO, C1-6 alkoxy, perhalo-C1-10 alkoxy, PhO, C1-10 heteroaryloxy, C1-10 heterocyclyloxy-C3-10 cycloalkyloxy, C1-6 alkylthio, C1-16 alkylsulfonyl, C1-6 alkylsulfamoyl, amino, mono - or di(C1-6 alkyl)amino, C1-6 sulfonylamino, C1-6 alkyl-carbonylamino, etc.; or two adjacent R2 taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; m = an integer from 0-5; R4 = H, F, Cl, R5-B-(CH2)n-; n = an integer from 0-6; B = a bond, (CHR6), O, S, SO2, CO, O-CO, CO-O, CO-NR6, R6N, R6NSO2, R6NCO, SO2NR6, R6NCONR7, O-CONR6 or R6NCO-O; R5 = H, CF3, cyano, each (un)substituted Ph, C1-10 heterocyclyl, C1-10 heteroaryl, or C3-10 cycloalkyl, etc.; R6 = H, C1-6 alkylsulfonyl, C1-6 alkyl or acceptable salts thereof, e.g., comprising reacting 6-(oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridines (II) (L = a leaving group and R1 and R4 are as defined above) with phenylboronic acids (III) and a transition metal catalyst. The compds. I prepared by the methods of the present invention are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine (33.0 g, 0.107 mol), 2,5-difluorophenylboronic acid (25.34 g, 0.1605 mol), Pd(PPh3)4 (12.36 g, 0.0107 mol), Et3N (22.37 mL, 0.1605 mol), 2B ethanol (495 mL), and water (33 mL), were added to a 2 L 4 neck round bottom flask (equipped with mech. stirring, nitrogen, heating mantle, temperature controller, and a condenser), stirred while heating to 65 to 70°, and kept stirring overnight at .apprx.70°. Two addnl. difluorophenylboronic acid (8.5 g, 0.054 mol) and Et3N (7.53 mL, 0.054 mol), were added and each time the reaction was allowed to proceed overnight at 70°. Toluene (30 mL) was added and the reaction was allowed to go overnight once again at 70°, treated with H2O (495 mL), and pot-granulated for 4 h at 20 to 25°. The solids were collected by vacuum filtration, washed with 2B ethanol/H2O (50:50) (25 mL of each), and dried in a vacuum oven at 45° for 4 ho under full vacuum to afford 14.4 g 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (40.6% yield, 93.4% purity by HPLC).

IT 668981-02-0P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α -tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-02-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 668981-03-1P, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine 668981-04-2P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride 668981-05-3P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate 668981-06-4P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate 668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of α -tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

10649255


RN 668981-03-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 668981-05-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 668981-06-4 CAPLUS


10649255

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 668981-07-5 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2

CRN 7664-93-9


CMF H2 O4 S



10649255

DN 137:232658
TI Preparation of 6-(phenylheterocyclyl)-[1,2,4]triazolo[4,3-a]pyridines as anti-inflammatory agents
IN Dombroski, Mark Anthony; Duplantier, Allen Jacob; Laird, Ellen Ruth; Letavic, Michael Anthony; McClure, Kim Francis
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2002072579 A1 20020919 WO 2002-IB424 20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1370559 A1 20031217 EP 2002-710260 20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EE 200300437 A 20040216 EE 2003-437 20020208
BR 2002007990 A 20040427 BR 2002-7990 20020208
US 2003096838 A1 20030522 US 2002-94760 20020311
US 6696464 B2 20040224
NO 2003003969 A 20031013 NO 2003-3969 20030908
PRAI US 2001-274840P P 20010309
WO 2002-IB424 W 20020208
OS MARPAT 137:232658
GI




AB Title compds. I [wherein Het = (un)substituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R2 = H, alkenyl, alkynyl, or (un)substituted (cyclo)alkyl, Ph, heteroaryl, or heterocyclyl, or amino; R3 = halo, (cyclo)alkyl(oxy), (perhalo)alkyl, alkenyl, alkynyl, Ph, heteroaryl(oxy), heterocycl(oxy), OH, (perhalo)alkoxy, PhO, alkylthio, alkylsulfonyl, alkylaminosulfonyl, NO2, (un)substituted amino, carbamoyl, etc.; n = 0-5; or pharmaceutically acceptable salts thereof] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase (no data). For example, 6-chloronicotinic acid was condensed with N,O-dimethylhydroxylamine-HCl (96%). Treatment of the amide with (i-Bu)2AlH gave the aldehyde (24%), which was coupled with (phenyl)(p-tolylsulfonyl)methylisocyanide to afforded 2-chloro-5-(4-phenyloxazol-5-yl)pyridine (71%). Conversion to the hydrazine (100%), followed by coupling with isobutyryl chloride and cyclization using POCl3 (32%), produced II. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).

IT 459447-61-1P, 3-Isopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine 459447-64-4P, 3-Ethyl-6-(4-m-tolylloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine 459447-66-6P, 3-Cyclopropyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 459447-67-7P, 3-Cyclobutyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine 459447-69-9P, 3-Difluoromethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine 459447-71-3P, 3-(Isoxazol-5-yl)-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine 459447-72-4P, 6-(4-Phenyloxazol-5-yl)-3-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridine 459447-73-5P,


10649255

3-Cyclobutyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
459447-74-6P, 3-Cyclopropyl-6-(4-phenyloxazol-5-yl)-
[1,2,4]triazolo[4,3-a]pyridine 459447-75-7P,
3-Ethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
459447-76-8P, 3-Ethyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-
[1,2,4]triazolo[4,3-a]pyridine 459447-77-9P,
6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-
a]pyridine 459447-78-0P, 3-Cyclobutyl-6-(4-m-tolyloxazol-5-yl)-
[1,2,4]triazolo[4,3-a]pyridine 459447-79-1P,
3-Isopropyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
459447-80-4P, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-
isopropyl-[1,2,4]triazolo[4,3-a]pyridine 459447-82-6P,
3-Cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)oxazol-5-yl]-
[1,2,4]triazolo[4,3-a]pyridine 459447-83-7P,
6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine
459447-84-8P, 3-Isopropyl-6-(2-methyl-4-phenyloxazol-5-yl)-
[1,2,4]triazolo[4,3-a]pyridine 459447-88-2P,
6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-
a]-pyridine 459447-89-3P, [6-[4-(4-Fluorophenyl)oxazol-5-yl]-
[1,2,4]triazol[4,3-a]pyridin-3-yl]acetic acid ethyl ester
459447-90-6P, 3-(2-Chlorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-
[1,2,4]triazol[4,3-a]pyridine 459447-91-7P, 6-[4-(2-Fluoro-5-
methylphenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine
459447-92-8P 459447-93-9P, 3-(2-Fluorophenyl)-6-[4-(m-
tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine 459447-94-0P,
[6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-
y1]dimethylamine 459447-95-1P, 6-[4-(4-Fluoro-3-
methylphenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine
459447-96-2P, 6-[4-(3-Chloro-4-fluorophenyl)oxazol-5-yl]-3-
isopropyl-[1,2,4]triazol[4,3-a]pyridine 459447-97-3P,
6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-
a]pyridine 459447-98-4P, 3-(2-Chlorophenyl)-6-[4-(4-
fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine
459448-00-1P, 6-[4-(3,4-Difluorophenyl)oxazol-5-yl]-3-isopropyl-
[1,2,4]triazol[4,3-a]pyridine 459448-01-2P, 6-[4-(4-
Fluorophenyl)-2-methyloxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine
459448-02-3P, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-phenyl-
[1,2,4]triazol[4,3-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(anti-inflammatory agent; preparation of (phenylheterocycl)triazolopyridin
es as anti-inflammatory agents)

RN 459447-61-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(4-phenyl-5-oxazolyl)-
(9CI) (CA INDEX NAME)




RN 459447-64-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(3-methylphenyl)-5-oxazolyl]-
(9CI) (CA INDEX NAME)



RN 459447-66-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluorophenyl)-5-


10649255

oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-67-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-69-9 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(difluoromethyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-71-3 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(5-isoxazolyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 459447-72-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-phenyl-5-oxazolyl)-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


10649255




RN 459447-73-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-(4-phenyl-5-oxazolyl)- (9CI)
(CA INDEX NAME)




RN 459447-74-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-(4-phenyl-5-oxazolyl)-
(9CI) (CA INDEX NAME)



RN 459447-75-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-(4-phenyl-5-oxazolyl)- (9CI) (CA
INDEX NAME)




RN 459447-76-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(4-fluorophenyl)-5-oxazolyl]-
(9CI) (CA INDEX NAME)




RN 459447-77-9 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(1-
methylethyl)- (9CI) (CA INDEX NAME)


10649255




RN 459447-78-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-79-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-80-4 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 459447-82-6 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)


10649255




RN 459447-83-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 459447-84-8 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(2-methyl-4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 459447-88-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 459447-89-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine-3-acetic acid, 6-[4-(4-fluorophenyl)-5-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)

10649255




RN 459447-90-6 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459447-91-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2-fluoro-5-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-92-8 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 459447-93-9 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-fluorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)


10649255




RN 459447-94-0 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridin-3-amine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 459447-95-1 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 459447-96-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-chloro-4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 459447-97-3 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

10649255




RN 459447-98-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 459448-00-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459448-01-2 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 459448-02-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)

10649255



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>